Medtronic Distribution Agreement

Advice newsletter to HCP employer – Letter intended to inform and receive employer approval when health professionals are recruited as lecturers or for consulting services, or when they are sponsored for an educational event or product training. Notification of The Use of Negotiators – Letter to inform Medtronic of all negotiators used or intended to be used in the execution of the distribution contract. This document is also listed in Appendix A of the Medtronic Distribution Agreement. The gastrointestinal and hepatological activities of Medtronic, part of the minimally invasive therapy group, and Q3 Medical have entered into an exclusive six-year agreement on the distribution of biodegradable stent ARCHIMEDES in the western EU, the United States and Japan; rights in other regions. Q3 Medical will strengthen its presence in Southeast Asia, Latin America, Eastern Europe and the Middle East. About Cosmo Pharmaceuticals Cosmo is a specialty pharmaceutical company that focuses on the treatment of certain gastrointestinal and endoscopy diseases. The company`s proprietary clinical development pipeline focuses specifically on innovative treatments for IBD, colonic acid infections and colon damage detection. Cosmo has also developed medical devices for endoscopy and recently partnered with Medtronic for the global distribution of its new artificial intelligence device, which will be used in colonoscopies and gelling processes. In addition, Cosmo is the licensee for the new process building agent, remimazolam, for the United States.

For more information about Cosmo and its products, visit the company`s website: www.cosmopharma.com Dublin, December 2, 2019 – Cosmo Pharmaceuticals NV (SIX: COPN) today announced that it has entered into a new global supply and distribution agreement for Eleview┬« with Medtronic (excluding Japan and Canada, or under EA Pharma and Pendopharm license), after in the meantime agreeing to the co-marketing agreement with Fujifilm. Eric Mangiardi, President and CEO of Q3 Medical, said: “We are pleased and happy to be with a global medical device organization like Medtronic. The conclusion of this agreement is an important step towards our goal of becoming the world`s leading developer of biodegradable implants. Mr. Mangiardi also explained; “ARCHIMEDES` promise is based on its potential to eliminate the second conventional plastic stent disposal process, which could reduce billions of global health care spending while improving patient care.” DUBLIN-(BUSINESS WIRE)– Dublin, Ireland-based Q3 Medical Devices Limited (“Q3 Medical”) announced today that it has entered into a distribution agreement with Medtronic plc for ARCHIMEDES, the first to commercialize fully biodegradable bile and pancreas as an alternative to conventional plastic stents. Due Diligence Quick Check – Registration to document the performance of due diligence with negotiators who are used or are to be used for the execution of the distribution contract.